Drug intelligence / Profile preview

MDH-115

Development stage: Unknown
Lead developer: MD Healthcare
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Ophthalmic

Overview

MDH-115 is a microbial extracellular vesicle (EV) nanotherapeutic being developed by MD Healthcare for the treatment of retinal diseases, including dry and wet age-related macular degeneration (AMD) and diabetic retinopathy (DR). The drug utilizes MD Healthcare's proprietary platform technology, which leverages extracellular vesicles derived from microorganisms to deliver therapeutic effects. These microbial EVs are designed to modulate biological pathways involved in inflammation and angiogenesis, which are key drivers of retinal degeneration. As of late 2024, MDH-115 is in Phase 1/2 development, with Phase 1 clinical trials initiated in the fourth quarter of 2024 and Phase 2 trials projected for late 2027.

Targets

MDM2 (Mouse double minute 2 homolog)

Beyond the preview

Go deeper on MDH-115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDH-115.

Explore the full profile